Cobo Dols, ManuelBeato Zambrano, CarmenCabezon-Gutierrez, LuisChicas-Sett, RodolfoBlancas Lopez-Barajas, Maria IsabelGarcia Navalon, Francisco JavierFirvida Perez, Jose LuisSerrano Bermudez, GalaTogores Torres, PilarDelgado Mingorance, IgnacioGiraldo Marin, AlexandraLibran Oriol, AnnaParedes Lario, AlfredoSanchez Maurino, PedroHiguera Gomez, OliverMoreno Munoz, DianaHuerta Gonzalez, IboneSanz-Yague, AlmudenaSoler Lopez, Begona2025-01-072025-01-072021-03-112045-435Xhttps://hdl.handle.net/10668/25895Objectives Naloxegol is a peripherally acting mu-opioid receptor antagonist (PAMORA) for treatment of opioid-induced constipation (OIC). The main objective was to analyse the long-term efficacy, quality of life (QOL) and safety of naloxegol in patients with cancer in a real-world study. Methods This one-year prospective study included patients older than 18 years, with active oncological disease who were under treatment with opioids for pain control and Karnofsky >= 50 and OIC with inadequate response to treatment with laxative (s). All the patients received treatment with naloxegol according to clinical criteria. The main efficacy objectives were measured by the patient assessment of constipation QOL questionnaire (PAC-QOL), the PAC symptoms (PAC-SYM), the response rate at day 15, and months 1-3-6-12, and global QOL (EuroQoL-5D-5L). Results A total of 126 patients (58.7% males) with a mean age of 61.5 years (95% CI 59.4 to 63.7) were included. PAC-SYM and PAC-QOL total score and all their dimensions improved from baseline (p= 50 and OIC with inadequate response to treatment with laxative (s). All the patients received treatment with naloxegol according to clinical criteria. The main efficacy objectives were measured by the patient assessment of constipation QOL questionnaire (PAC-QOL), the PAC symptoms (PAC-SYM), the response rate at day 15, and months 1-3-6-12, and global QOL (EuroQoL-5D-5L). Results A total of 126 patients (58.7% males) with a mean age of 61.5 years (95% CI 59.4 to 63.7) were included. PAC-SYM and PAC-QOL total score and all their dimensions improved from baseline (penAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/constipationcancerpainInduced bowel dysfunctionPooled analysisNoncancer painPrevalencePathophysiologyValidationManagementDisordersSeverityresearch article33707299open access10.1136/bmjspcare-2020-0028162045-4368https://spcare.bmj.com/content/bmjspcare/early/2021/03/10/bmjspcare-2020-002816.full.pdf727473500001